Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α ( PIK3CA )
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The p110α catalytic subunit ( PIK3CA ) is one of the most frequently mutated genes in cancer. We have examined the activation of the wild-type p110α/p85α and a spectrum of oncogenic mutants using hydrogen/deuterium exchange mass spectrometry (HDX-MS). We find that for the wild-type enzyme, the natural transition from an inactive cytosolic conformation to an activated form on membranes entails four distinct events. Analysis of oncogenic mutations shows that all up-regulate the enzyme by enhancing one or more of these dynamic events. We provide the first insight into the activation mechanism by mutations in the linker between the adapter-binding domain (ABD) and the Ras-binding domain (RBD) (G106V and G118D). These mutations, which are common in endometrial cancers, enhance two of the natural activation events: movement of the ABD and ABD–RBD linker relative to the rest of the catalytic subunit and breaking the C2–iSH2 interface on binding membranes. C2 domain mutants (N345K and C420R) also mimic these events, even in the absence of membranes. A third event is breaking the nSH2–helical domain contact caused by phosphotyrosine-containing peptides binding to the enzyme, which is mimicked by a helical domain mutation (E545K). Interaction of the C lobe of the kinase domain with membranes is the fourth activation event, and is potentiated by kinase domain mutations (e.g., H1047R). All mutations increased lipid binding and basal activity, even mutants distant from the membrane surface. Our results elucidate a unifying mechanism in which diverse PIK3CA mutations stimulate lipid kinase activity by facilitating allosteric motions required for catalysis on membranes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, a number of frequent cancer mutations in PIK3CA upregulate the PI3K activity by mimicking or enhancing one or more conformational events that accompany the physiological activation [77].”
From Phosphatidylinositol(4,5)bisphosphate: diverse functions at the plasma membrane (2020) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
PTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C.-H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 560
Yu, J., Zhang, Y., McIlroy, J., Rordorf-Nikolic, T., Orr, G. A., & Backer, J. M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1379 · Cited by 520 · cited 1×
“The activity of p110α is stringently regulated by a tightly associated p85 regulatory subunit, which stabilizes the enzyme, inhibits lipid kinase activity, and allows activation downstream of receptor tyrosine kinases (RTKs) (10, 11).”
BackgroundStructural insights into phosphoinositide 3-kinase catalysis and signalling
Walker, E. H., Perisic, O., Ried, C., Stephens, L., & Williams, R. L. (1999) · Nature · doi:10.1038/46319 · Cited by 494 · cited 1×
“The p110α catalytic subunit is composed of an adapter-binding domain (ABD), a Ras-binding domain (RBD), a C2 domain, helical domain, and a kinase domain (17).”
BackgroundSelf-citationCheung, L. W. T., Hennessy, B. T., Li, J., Yu, S., Myers, A. P., Djordjevic, B., Lu, Y., Stemke-Hale, K., Dyer, M. D., Zhang, F., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0039 · Cited by 470
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437 · cited 1×
“Indeed, a previous study showed that combined mutations in the helical and kinase domain (E545K and H1047R) greatly synergize in cell transformation (6).”
BackgroundTransformation of Chicken Cells by the Gene Encoding the Catalytic Subunit of PI 3-Kinase
Chang, H. W., Aoki, M., Fruman, D., Auger, K. R., Bellacosa, A., Tsichlis, P. N., Cantley, L. C., Roberts, T. M., & Vogt, P. K. (1997) · Science · doi:10.1126/science.276.5320.1848 · Cited by 412 · cited 1×
“T oncogenic potential of phosphoinositide 3-kinases (PI3Ks) was first established when it was shown that an activated form of the PI3K isoform p110α (v-P3K) was encoded by an avian sarcoma virus and that this viral gene and its cellular counterpart can cause cell transformation (1).”
BackgroundMechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit
Miled, N., Yan, Y., Hon, W.-C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H. J., Backer, J. M., & Williams, R. L. (2007) · Science · doi:10.1126/science.1135394 · Cited by 410 · cited 5×
“The binding of phosphorylated YXXM motifs in activated RTKs and adapter proteins disrupts the inhibitory contact between the nSH2 and catalytic subunit (12, 13).”
BackgroundInfluentialSelf-citationRare cancer-specific mutations in PIK3CA show gain of function
Gymnopoulos, M., Elsliger, M.-A., & Vogt, P. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701005104 · Cited by 376 · cited 3×
“The N345K mutant is located at the interface of the iSH2 and C2 domains, and it causes a disruption of this interface, similar to the N564D mutant in the iSH2 domain (19, 21).”
BackgroundAnalysis of Protein Conformation and Dynamics by Hydrogen/Deuterium Exchange MS
Engen, J. R. (2009) · Analytical Chemistry · doi:10.1021/ac901154s · Cited by 369 · cited 1×
“Hydrogen/deuterium exchange mass spectrometry (HDX-MS) has become a powerful tool for understanding the dynamics of complex protein systems (22) and it is particularly useful for understanding protein–lipid interactions (23–27).”
BackgroundStructural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases
Vadas, O., Burke, J. E., Zhang, X., Berndt, A., & Williams, R. L. (2011) · Science Signaling · doi:10.1126/scisignal.2002165 · Cited by 299
Self-citationA frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane
Mandelker, D., Gabelli, S. B., Schmidt-Kittler, O., Zhu, J., Cheong, I., Huang, C.-H., Kinzler, K. W., Vogelstein, B., & Amzel, L. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908444106 · Cited by 293
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Jaiswal, B. S., Janakiraman, V., Kljavin, N. M., Chaudhuri, S., Stern, H. M., Wang, W., Kan, Z., Dbouk, H. A., Peters, B. A., Waring, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.016 · Cited by 289 · cited 1×
“The p85 subunit is also somatically mutated in several tumor types (14, 15), with frequent mutations in primary endometrial tumors (14).”
BackgroundPrognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Liao, X., Morikawa, T., Lochhead, P., Imamura, Y., Kuchiba, A., Yamauchi, M., Nosho, K., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2410 · Cited by 258
PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
Urick, M. E., Rudd, M. L., Godwin, A. K., Sgroi, D., Merino, M., & Bell, D. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0549 · Cited by 230 · cited 1×
“The p85 subunit is also somatically mutated in several tumor types (14, 15), with frequent mutations in primary endometrial tumors (14).”
BackgroundA Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas
Rudd, M. L., Price, J. C., Fogoros, S., Godwin, A. K., Sgroi, D. C., Merino, M. J., & Bell, D. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0540 · Cited by 222 · cited 5×
“Gain-of-function mutations resulting in increased oncogenic transformation are associated with all of these domains (18, 19).”
BackgroundInfluentialKinross, K. M., Montgomery, K. G., Kleinschmidt, M., Waring, P., Ivetac, I., Tikoo, A., Saad, M., Hare, L., Roh, V., Mantamadiotis, T., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59309 · Cited by 214 · cited 1×
“Mice with the most common p110α mutation (H1047R) expressed in ovaries develop hyperplasias, but not tumors, whereas coupled with the loss of the lipid phosphatase PTEN results in rapid ovarian tumor development (9).”
BackgroundIlic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211 · cited 1×
“Instead, mutations elsewhere in the pathway that bypass inhibition are common (37).”
BackgroundStructure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism
Zhang, X., Vadas, O., Perisic, O., Anderson, K. E., Clark, J., Hawkins, P. T., Stephens, L. R., & Williams, R. L. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.01.026 · Cited by 210 · cited 1×
“This is in contrast to p110β and p110δ, which have inhibitory contacts with both the nSH2 and cSH2 (25, 34).”
ResultSelf-citationDirect positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase
Chagpar, R. B., Links, P. H., Pastor, M. C., Furber, L. A., Hawrysh, A. D., Chamberlain, M. D., & Anderson, D. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908899107 · Cited by 194 · cited 5×
“Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer.”
BackgroundInfluentialRegulation of the p85/p110α Phosphatidylinositol 3′-Kinase
Yu, J., Wjasow, C., & Backer, J. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30199 · Cited by 181 · cited 3×
“The N-terminal SH2 domain (nSH2) and the inter-SH2 domain (iSH2) of p85 are the minimal fragment of the regulatory subunit required for full inhibition of p110α lipid kinase activity (11).”
BackgroundSun, M., Hillmann, P., Hofmann, B. T., Hart, J. R., & Vogt, P. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009652107 · Cited by 151 · cited 1×
“These p85 mutations lead to stimulation of the associated catalytic subunit (16).”
BackgroundRegulation of lipid binding underlies the activation mechanism of class IA PI3-kinases
Hon, W.-C., Berndt, A., & Williams, R. L. (2012) · Oncogene · doi:10.1038/onc.2011.532 · Cited by 129 · cited 7×
“S4, S5C, and S6C), in regions either predicted to be part of lipidbinding surface (loop from 864 to 875) (13) or shown to be critical for membrane interaction (very C terminus of p110α) (5).”
BackgroundInfluentialSelf-citationCa2+-Signaling Cycle of a Membrane-Docking C2 Domain
Nalefski, E. A., Slazas, M. M., & Falke, J. J. (1997) · Biochemistry · doi:10.1021/bi9717340 · Cited by 117 · cited 1×
“We performed protein– lipid FRET experiments to measure lipid binding (29).”
MethodCarson, J. D., Van Aller, G., Lehr, R., Sinnamon, R. H., Kirkpatrick, R. B., Auger, K. R., Dhanak, D., Copeland, R. A., Gontarek, R. R., Tummino, P. J., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070681 · Cited by 116
Oncogenic signaling of class I PI3K isoforms
Denley, A., Kang, S. G., Kärst, U., & Vogt, P. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210918 · Cited by 114 · cited 1×
“One interesting exception was decreased HDX for N345K in the C2 domain, which has been postulated to interact with membranes (5, 28).”
BackgroundBurke, J. E., Vadas, O., Berndt, A., Finegan, T., Perisic, O., & Williams, R. L. (2011) · Structure · doi:10.1016/j.str.2011.06.003 · Cited by 109 · cited 5×
“Deuterium incorporation was quantified on pepsin-digested peptides separated on a reversed-phase ultra performance liquid chromatography (UPLC), as described previously (25).”
BackgroundMethodResultInfluentialSelf-citationWu, H., Shekar, S. C., Flinn, R. J., El-Sibai, M., Jaiswal, B. S., Sen, K. I., Janakiraman, V., Seshagiri, S., Gerfen, G. J., Girvin, M. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902369106 · Cited by 85 · cited 2×
“The N345K mutant is located at the interface of the iSH2 and C2 domains, and it causes a disruption of this interface, similar to the N564D mutant in the iSH2 domain (19, 21).”
BackgroundLee, J. Y., Chiu, Y.-H., Asara, J., & Cantley, L. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107747108 · Cited by 83 · cited 1×
“Recent studies have identified novel aspects of PI3K regulation, for example, by phosphorylation of both the nSH2 and cSH2 domains of p85 downstream of PKC (30) and the cSH2 domain by IKK (31), leading to decreased affinity for tyrosine-phosphorylated activators.”
BackgroundComb, W. C., Hutti, J. E., Cogswell, P., Cantley, L. C., & Baldwin, A. S. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.010 · Cited by 70
Hsu, Y.-H., Burke, J. E., Li, S., Woods, V. L., & Dennis, E. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.021857 · Cited by 69
Self-citationBurke, J. E., Karbarz, M. J., Deems, R. A., Li, S., Woods, V. L., & Dennis, E. A. (2008) · Biochemistry · doi:10.1021/bi8000962 · Cited by 62
Self-citationBurke, J. E., Hsu, Y.-H., Deems, R. A., Li, S., Woods, V. L., & Dennis, E. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804492200 · Cited by 59
Self-citationFunctional differences between two classes of oncogenic mutation in the PIK3CA gene
Chaussade, C., Cho, K., Mawson, C., Rewcastle, G. W., & Shepherd, P. R. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.02.081 · Cited by 56
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer
Yang, X., Turke, A. B., Qi, J., Song, Y., Rexer, B. N., Miller, T. W., Janne, P. A., Arteaga, C. L., Cantley, L. C., Engelman, J. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0445 · Cited by 14 · cited 1×
“Indeed, it has been shown that E545K is preferentially recruited to IRS1 compared with the WT enzyme (36), and in a cellular context E545K may be more sensitive to RTK signaling.”
BackgroundMan, P., Montagner, C., Vitrac, H., Kavan, D., Pichard, S., Gillet, D., Forest, É., & Forge, V. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.09.042 · Cited by 13
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“In contrast, E542K and E545Kmutations disrupt the inhibitory interface with the N-SH2 domains of the regulatory subunits (Burke et al., 2012; Miled et al., 2007).”
BackgroundPI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 822
“Helical domain mutations increase catalytic activity by reducing the repression of p110α by p85 (10) or facilitating the interaction of p110α with IRS-1 (11), whereas kinase domain mutations increase the retention of p110α at the plasma membrane (12).”
BackgroundTewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage
Angulo, I., Vadas, O., Garçon, F., Banham-Hall, E., Plagnol, V., Leahy, T. R., Baxendale, H., Coulter, T., Curtis, J., Wu, C., et al. (2013) · Science · doi:10.1126/science.1243292 · Cited by 636
Self-citation
Metadata
- Authors
- Burke, J. E., Perisic, O., Masson, G. R., Vadas, O., & Williams, R. L.
- Affiliations
- MRC Laboratory of Molecular Biology (GB)
- Laboratory of Molecular Biology, Medical Research Council, Cambridge CB2 0QH, United Kingdom
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-09-04
- Volume
- 109
- Issue
- 38
- Pages
- 15259-15264
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3458343
- OpenAlex
- W2135784953
- Cited by
- 300
- References
- 37
- Citations by year
- 2026: 15 · 2025: 15 · 2024: 22 · 2023: 29 · 2022: 35 · 2021: 23 · 2020: 21 · 2019: 22 · 2018: 22 · 2017: 27 · 2016: 11 · 2015: 27 · 2014: 15 · 2013: 13 · 2012: 3
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Funders
- British Heart Foundation (PG/11/109/29247)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (134202)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- PIK3CA, p110α, oncogenic mutations, allosteric regulation, protein conformational dynamics, Ras-binding domain, C2 domain, membrane binding, endometrial cancer, hydrogen-deuterium exchange mass spectrometry
- MeSH terms
- Allosteric Site, Animals, Catalysis, Cytosol, Enzyme Activation, Female, Humans, Kinetics, Lipids, Models, Molecular, Molecular Conformation, Motion, Mutation, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Endometrial Neoplasms, Protein Structure, Tertiary, Phosphatidylinositol 3-Kinases, Catalytic Domain, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.